BTIG Reiterates Buy on Climb Bio, Maintains $19 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.7%

Neg 0% Neu 88.7% Pos 0%

BTIG analyst Julian Harrison reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $19 price target.

Comments

No comments yet. Be the first!